{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T03:04:01Z","timestamp":1649214241073},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1007\/s00120-006-1121-8","type":"journal-article","created":{"date-parts":[[2006,6,30]],"date-time":"2006-06-30T19:18:54Z","timestamp":1151695134000},"page":"847-851","source":"Crossref","is-referenced-by-count":1,"title":["Vergleich der Effektivit\u00e4t und Vertr\u00e4glichkeit von Solifenacin und Tolterodin retard in der Behandlung der \u00fcberaktiven Blase"],"prefix":"10.1007","volume":"45","author":[{"given":"M.","family":"Goepel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"1121_CR1","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1097\/01.ju.0000140729.07840.16","volume":"172","author":"Cardozo","year":"2004","unstructured":"Cardozo L, Haab F, Chapple C et al. (2004) Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent Solifenacin succinate in patients with overactive bladder. J Urology 172: 1919\u20131924","journal-title":"J Urology"},{"key":"1121_CR2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1464-410X.2004.04606.x","volume":"93","author":"Chapple","year":"2004","unstructured":"Chapple CR, Rechberger T, Al-Shukri S et al. (2004) Randomized, double-blind placebo- and Tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Intern 93: 303\u2013310","journal-title":"BJU Intern"},{"key":"1121_CR3","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.eururo.2005.05.015","volume":"48","author":"Chapple","year":"2005","unstructured":"Chapple CR, Martinez-Garcia R, Selvaggi L et al. (2005) A comparison of the efficacy and tolerability of Solifenacin succinate and extended release Tolterodine at treating overactive bladder syndrome: results of the STAR Trial. European Urology 48: 464\u2013470","journal-title":"European Urology"},{"key":"1121_CR4","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.eururo.2005.09.013","volume":"49","author":"Chapple","year":"2006","unstructured":"Chapple CR (2006) Letter to the Editor. Reply to Jonas U, Rackley RR. Eur Urology 49: 187\u2013190","journal-title":"Eur Urology"},{"key":"1121_CR5","doi-asserted-by":"crossref","first-page":"687","DOI":"10.4065\/78.6.687","volume":"78","author":"Diokno","year":"2003","unstructured":"Diokno AC (2003) Prospective, randomized, double-blind study of the efficacy and tolerability of the extetended-release formulations of Oxybutynin and Tolterodine for overactive bladder: Results of the OPERA trial. Mayo Clin Proc 78: 687\u2013695","journal-title":"Mayo Clin Proc"},{"key":"1121_CR6","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.urology.2004.02.029","volume":"64","author":"Khullar","year":"2004","unstructured":"Khullar V (2004) Treatment of urge-predominant mixed urinary incontinence with Tolterodine extended release: A randomized, placebo-controlled trial. Urology 64: 269\u2013275","journal-title":"Urology"},{"key":"1121_CR7","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S0149-2918(02)85137-2","volume":"24","author":"Siami","year":"2002","unstructured":"Siami P, Seidman LS, Lama D (2002) A multicenter, prospective, open-label study of Tolterodine extended-release 4\u00a0mg of overactive bladder: The speed of onset of therapeutic assessment trial (STAT). Clinical Therapeutics 24: 616\u2013628","journal-title":"Clinical Therapeutics"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-006-1121-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00120-006-1121-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-006-1121-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T10:58:40Z","timestamp":1558609120000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00120-006-1121-8"}},"subtitle":["Kommentar zur STAR-Studie"],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":7,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["1121"],"URL":"https:\/\/doi.org\/10.1007\/s00120-006-1121-8","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7]]}}}